Premium
Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12
Author(s) -
Micheletti R.G.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.18437
Subject(s) - hidradenitis suppurativa , adalimumab , medicine , dermatology , disease
Linked Article: Jemec et al . Br J Dermatol 2019; 181 :967–975.